-
公开(公告)号：US20080045554A1
公开(公告)日：2008-02-21
申请号：US11766981
申请日：2007-06-22
申请人： Changsheng Zheng , Chu-Biao Xue , Ganfeng Cao , Michael Xia , Anlai Wang , Hai Ye , Brian Metcalf
发明人： Changsheng Zheng , Chu-Biao Xue , Ganfeng Cao , Michael Xia , Anlai Wang , Hai Ye , Brian Metcalf
IPC分类号： A61K31/495 , A61P3/00 , C07D239/00
CPC分类号： C07D487/14
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
摘要翻译： 本发明涉及作为HM74a受体的激动剂的嘌呤酮衍生物。 还提供了使用本文化合物及其药学上可接受的盐来治疗疾病的组合物和方法。
-
22.发明授权公开(公告)号：US07834021B2
公开(公告)日：2010-11-16
申请号：US10535795
申请日：2003-11-26
申请人： Chu-Biao Xue , Brian W. Metcalf , Ganfeng Cao
发明人： Chu-Biao Xue , Brian W. Metcalf , Ganfeng Cao
IPC分类号： C07D239/00 , A01N43/54
CPC分类号： C07D491/107 , C07D207/14 , C07D401/08 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/08 , C07D403/10 , C07D405/04 , C07D405/08 , C07D405/10 , C07D405/14 , C07D409/08 , C07D413/08 , C07D413/10 , C07D413/14 , C07D417/08 , C07D417/10 , C07D417/14 , C07D491/10 , C07D495/10
摘要： The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of chemokine receptors and more specifically as a modulator of the CCR2 and/or CCR5 receptor. The compounds and compositions of the invention may bind to chemokine receptors, e.g., the CCR2 and/or CCR5 chemokine receptors, and are useful for treating diseases associated with chemokine, e.g., CCR2 and/or CCR5, activity, such as atherosclerosis, restenosis, lupus, organ transplant rejection and rheumatoid arthritis.
摘要翻译： 本发明涉及可用作趋化因子受体调节剂的式I的3-氨基吡咯烷衍生物（其中R1，R2，R3，R4，R5，R6，R7，R8，X，Y和X如本文所定义） 活动。 特别地，这些化合物可用作趋化因子受体的调节剂，更具体地可用作CCR2和/或CCR5受体的调节剂。 本发明的化合物和组合物可以结合趋化因子受体，例如CCR2和/或CCR5趋化因子受体，并且可用于治疗与趋化因子（例如CCR2和/或CCR5）相关的疾病，例如动脉粥样硬化，再狭窄， 狼疮，器官移植排斥和类风湿关节炎。
-
公开(公告)号：US20080045555A1
公开(公告)日：2008-02-21
申请号：US11766990
申请日：2007-06-22
申请人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
发明人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
IPC分类号： A61K31/505 , A61P7/00 , C07D239/00
CPC分类号： C07D487/14 , C07D403/14 , C07D487/04
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
-
公开(公告)号：US07462624B2
公开(公告)日：2008-12-09
申请号：US11766990
申请日：2007-06-22
申请人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
发明人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
IPC分类号： A01N43/54 , A61K31/505 , C07D239/00 , C07D471/00 , C07D487/00 , C07D491/00
CPC分类号： C07D487/14 , C07D403/14 , C07D487/04
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
摘要翻译： 本发明涉及作为HM74a受体的激动剂的嘌呤酮衍生物。 还提供了使用本文化合物及其药学上可接受的盐来治疗疾病的组合物和方法。
-
公开(公告)号：US07902205B2
公开(公告)日：2011-03-08
申请号：US12237794
申请日：2008-09-25
申请人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
发明人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
IPC分类号： A01N43/54 , A61K31/505 , C07D491/00
CPC分类号： C07D487/14 , C07D403/14 , C07D487/04
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
-
公开(公告)号：US07863285B2
公开(公告)日：2011-01-04
申请号：US12237807
申请日：2008-09-25
申请人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
发明人： Chu-Biao Xue , Brian Metcalf , Anlai Wang , Changsheng Zheng , Ganfeng Cao , Ke Zhang
IPC分类号： A61K31/505
CPC分类号： C07D487/14 , C07D403/14 , C07D487/04
摘要： The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
摘要翻译： 本发明涉及作为HM74a受体的激动剂的嘌呤酮衍生物。 还提供了使用本文化合物及其药学上可接受的盐来治疗疾病的组合物和方法。
-
公开(公告)号：US20050261310A1
公开(公告)日：2005-11-24
申请号：US11104041
申请日：2005-04-12
申请人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian Metcalf
发明人： Chu-Biao Xue , Ganfeng Cao , Taisheng Huang , Lihua Chen , Ke Zhang , Anlai Wang , David Meloni , Rajan Anand , Joseph Glenn , Brian Metcalf
IPC分类号： A61K31/496 , A61K45/06 , C07D401/06 , C07D401/14 , C07D417/14 , C07D471/04 , C07D43/04
CPC分类号： C07D401/14 , A61K31/496 , A61K31/502 , A61K31/506 , A61K45/06 , C07D401/06 , C07D417/14 , C07D471/04 , A61K2300/00
摘要： The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.
摘要翻译： 本发明涉及式I化合物：其中可变取代基在本文中定义，其调节趋化因子受体如CCR5的活性或与其结合。 在一些实施方案中，本发明的化合物对CCR5是选择性的。 该化合物可用于例如治疗与趋化因子受体表达或活性相关的疾病，例如炎性疾病，免疫疾病和病毒感染。
-
公开(公告)号：US09487521B2
公开(公告)日：2016-11-08
申请号：US13605331
申请日：2012-09-06
申请人： Jiacheng Zhou , Yongzhong Wu , Pingli Liu , Ganfeng Cao
发明人： Jiacheng Zhou , Yongzhong Wu , Pingli Liu , Ganfeng Cao
IPC分类号： C07D487/04 , C07D491/10
CPC分类号： C07D491/113 , C07D401/06 , C07D487/04 , C07D491/10
摘要： This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
-
公开(公告)号：US20130060026A1
公开(公告)日：2013-03-07
申请号：US13605331
申请日：2012-09-06
申请人： Jiacheng Zhou , Yongzhong Wu , Pingli Liu , Ganfeng Cao
发明人： Jiacheng Zhou , Yongzhong Wu , Pingli Liu , Ganfeng Cao
IPC分类号： C07D487/04 , C07D491/113 , C07D401/06 , C07F7/02
CPC分类号： C07D491/113 , C07D401/06 , C07D487/04 , C07D491/10
摘要： This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.052 秒)
